RU2014113924A - Мутанты эндостатина с мутациями в сайтах связывания атф - Google Patents
Мутанты эндостатина с мутациями в сайтах связывания атф Download PDFInfo
- Publication number
- RU2014113924A RU2014113924A RU2014113924/10A RU2014113924A RU2014113924A RU 2014113924 A RU2014113924 A RU 2014113924A RU 2014113924/10 A RU2014113924/10 A RU 2014113924/10A RU 2014113924 A RU2014113924 A RU 2014113924A RU 2014113924 A RU2014113924 A RU 2014113924A
- Authority
- RU
- Russia
- Prior art keywords
- mutant
- endostatin
- seq
- variant
- amino acid
- Prior art date
Links
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 title claims abstract 37
- 108010079505 Endostatins Proteins 0.000 title claims abstract 37
- 230000035772 mutation Effects 0.000 title claims abstract 8
- 238000000034 method Methods 0.000 claims abstract 25
- 108091006112 ATPases Proteins 0.000 claims abstract 15
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims abstract 15
- 230000000694 effects Effects 0.000 claims abstract 15
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 13
- 230000004071 biological effect Effects 0.000 claims abstract 6
- 239000012634 fragment Substances 0.000 claims abstract 5
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 2
- 230000029918 bioluminescence Effects 0.000 claims abstract 2
- 238000005415 bioluminescence Methods 0.000 claims abstract 2
- 238000010353 genetic engineering Methods 0.000 claims abstract 2
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 claims abstract 2
- 229940107698 malachite green Drugs 0.000 claims abstract 2
- 238000012986 modification Methods 0.000 claims abstract 2
- 230000004048 modification Effects 0.000 claims abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract 2
- 239000010452 phosphate Substances 0.000 claims abstract 2
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 101500026378 Homo sapiens Endostatin Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000010595 endothelial cell migration Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- -1 aromatic amino acid Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110280441 | 2011-09-09 | ||
| CN201110280441.8 | 2011-09-09 | ||
| PCT/CN2012/081210 WO2013034116A1 (zh) | 2011-09-09 | 2012-09-10 | 对atp结合位点进行突变的血管内皮抑制素突变体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014113924A true RU2014113924A (ru) | 2015-10-20 |
Family
ID=47831548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014113924/10A RU2014113924A (ru) | 2011-09-09 | 2012-09-10 | Мутанты эндостатина с мутациями в сайтах связывания атф |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10647968B2 (enExample) |
| EP (1) | EP2754718B1 (enExample) |
| JP (1) | JP6336389B2 (enExample) |
| CN (2) | CN117987505A (enExample) |
| AU (1) | AU2012306826B2 (enExample) |
| CA (1) | CA2848118C (enExample) |
| IL (1) | IL231419A0 (enExample) |
| RU (1) | RU2014113924A (enExample) |
| WO (1) | WO2013034116A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104926933B (zh) * | 2014-03-19 | 2018-09-07 | 北京仁和天通生物科技有限公司 | Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用 |
| CA3003760A1 (en) * | 2014-11-03 | 2016-05-12 | Tsinghua University | Drug for inhibiting adipose cell differentiation and insulin resistance |
| WO2016127948A1 (zh) * | 2015-02-13 | 2016-08-18 | 清华大学 | 一种重组蛋白质药物的分子设计 |
| CN110452295B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 抗肿瘤蛋白内皮抑素的衍生物 |
| WO2018086603A1 (zh) * | 2016-11-10 | 2018-05-17 | 北京普罗吉生物科技发展有限公司 | 聚乙二醇化血管内皮抑制素类似物及其应用 |
| CA3103035A1 (en) * | 2017-07-30 | 2019-02-07 | Tsinghua University | Medication for inhibiting dna-pkcs |
| CN114645025B (zh) * | 2022-04-13 | 2023-12-22 | 南开大学 | 一种人源atp合成酶的纯化方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1322246A (zh) * | 1997-12-08 | 2001-11-14 | 贝斯以色列护理医疗中心 | 静息蛋白及其使用方法 |
| WO2000067771A1 (en) * | 1999-05-06 | 2000-11-16 | The Burnham Institute | Antiangiogenic endostatin peptides, endostatin variants and methods of use |
| CN1237072C (zh) * | 2000-05-22 | 2006-01-18 | 烟台荣昌生物工程有限公司 | 生产内皮抑制素的方法 |
| JP4511108B2 (ja) * | 2002-05-31 | 2010-07-28 | オンコリクス インコーポレイテッド | ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質 |
| CN100475270C (zh) * | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
| CN101143894A (zh) * | 2007-06-22 | 2008-03-19 | 中国药科大学 | 高效抑制血管生成多肽及其物理化学修饰方法和应用 |
| WO2009145489A2 (ko) * | 2008-04-04 | 2009-12-03 | 주식회사 프로셀제약 | 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 |
| CN101256139A (zh) * | 2008-04-18 | 2008-09-03 | 山东先声麦得津生物制药有限公司 | 一种血管内皮抑制素生物活性的检测方法 |
| CN101890155B (zh) * | 2010-05-25 | 2012-07-25 | 江苏先声药物研究有限公司 | 一种药物组合物及其应用 |
-
2012
- 2012-09-10 WO PCT/CN2012/081210 patent/WO2013034116A1/zh not_active Ceased
- 2012-09-10 RU RU2014113924/10A patent/RU2014113924A/ru not_active Application Discontinuation
- 2012-09-10 CN CN202410186085.0A patent/CN117987505A/zh active Pending
- 2012-09-10 AU AU2012306826A patent/AU2012306826B2/en active Active
- 2012-09-10 CN CN201280078261.4A patent/CN108291248B/zh active Active
- 2012-09-10 CA CA2848118A patent/CA2848118C/en active Active
- 2012-09-10 US US14/343,694 patent/US10647968B2/en active Active
- 2012-09-10 EP EP12830317.9A patent/EP2754718B1/en active Active
- 2012-09-10 JP JP2014528847A patent/JP6336389B2/ja active Active
-
2014
- 2014-03-09 IL IL231419A patent/IL231419A0/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2754718A1 (en) | 2014-07-16 |
| US10647968B2 (en) | 2020-05-12 |
| AU2012306826A1 (en) | 2014-04-03 |
| CN108291248A (zh) | 2018-07-17 |
| US20150197733A9 (en) | 2015-07-16 |
| EP2754718B1 (en) | 2017-12-13 |
| WO2013034116A1 (zh) | 2013-03-14 |
| CA2848118C (en) | 2023-09-05 |
| CN108291248B (zh) | 2024-03-08 |
| HK1251864A1 (zh) | 2019-04-26 |
| JP6336389B2 (ja) | 2018-06-06 |
| US20140308263A1 (en) | 2014-10-16 |
| CA2848118A1 (en) | 2013-03-14 |
| AU2012306826B2 (en) | 2018-01-04 |
| IL231419A0 (en) | 2014-04-30 |
| JP2014531897A (ja) | 2014-12-04 |
| CN117987505A (zh) | 2024-05-07 |
| EP2754718A4 (en) | 2015-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014113924A (ru) | Мутанты эндостатина с мутациями в сайтах связывания атф | |
| JP6071099B1 (ja) | 血管の新生又は成長を抑制する融合タンパク質及びその用途 | |
| JP2021073281A (ja) | 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体 | |
| CN114671941B (zh) | 神经生长因子突变体 | |
| WO2016019726A1 (zh) | 低免疫原性抗TNF-α全人源单抗及其应用 | |
| EP4110385A1 (en) | Compositions comprising ltb and pathogenic antigens, and use thereof | |
| JP2014531897A5 (enExample) | ||
| CN113717277B (zh) | 一种肿瘤抑制肽 | |
| CN114375333B (zh) | 包含赖氨酰氧化酶的前肽的组合物及其用途 | |
| JP7006968B2 (ja) | 腫瘍壊死因子αの高親和性ペプチド及びその適用 | |
| CN105861462B (zh) | 一种多肽及其应用 | |
| Arevalo et al. | Worldwide Geographical and Temporal Analysis of SARS-CoV-2 Haplotypes shows Differential Distribution Patterns | |
| AU2023285422A1 (en) | Ubiquitin high affinity cyclic peptides and methods of use thereof | |
| Sfera et al. | The Matryoshka code of COVID-19 mRNA vaccines: overlapping viral sequences? | |
| JP2024521368A (ja) | 環状ＲＮＡ Ｃｉｒｃ－ＡＣＥ２翻訳によるポリペプチド及びその使用 | |
| CN116925226A (zh) | 抗msln抗体、方法及应用 | |
| Pur Rahim et al. | Characterization of Iranian isolates of grapevine leaf roll associated virus-3. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160906 |